Lack of association between pro-inflammatory cytokine (IL-6, IL-8 and TNF-α) gene polymorphisms and Graves' disease

Summary Graves’ disease (GD) is a common, autoimmune disease involving the thyroid gland, and it has been previously suggested that pro‐inflammatory cytokines are involved in the disease's pathogenesis. The aim of this study was to test whether the interleukin (IL)‐6 gene promoter region, or tu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of immunogenetics 2005-12, Vol.32 (6), p.343-347
Hauptverfasser: Chen, R.-H., Chen, W.-C., Wang, T.-Y., Tsai, C.-H., Tsai, F.-J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Graves’ disease (GD) is a common, autoimmune disease involving the thyroid gland, and it has been previously suggested that pro‐inflammatory cytokines are involved in the disease's pathogenesis. The aim of this study was to test whether the interleukin (IL)‐6 gene promoter region, or tumour necrosis factor (TNF)‐α or IL‐8 gene 3′‐untranslated region (3′‐UTR) polymorphisms could provide useful genetic markers for an individual's susceptibility to GD. A normal control group of 60 healthy people and 95 patients featuring GD were examined. Polymerase chain reaction (PCR)‐based restriction analysis was performed for the three gene polymorphisms using endonucleases BsrBI, NcoI and ApaLI, respectively. We found no significant difference between the frequencies of genotype and allelic variants for the IL‐6 gene promoter (−572 G/C), the TNF‐α gene promoter (−308 A/G) and the IL‐8 gene 3′‐UTR (2767 A/G) for GD patients and for normal controls. Cytokines are a large group of proteins that may elicit multiple effects upon immunological reactions. It still appears to be very worthwhile to continue to aggressively search for cytokine gene polymorphisms in order to predict the development of such disease.
ISSN:1744-3121
1744-313X
DOI:10.1111/j.1744-313X.2005.00536.x